Provider, patient and public benefits from a NICE appraisal of bevacizumab (Avastin)
There are several good reasons for the UK Department of Health to recommend the appraisal of bevacizumab for the treatment of eye conditions by the National Institute for Health and Clinical Excellence. These reasons will extend to other drugs when similar situations arise in the future.
- chemical and biological weapons
- drugs and drug industry
- international affairs
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Competing interests None.
Provenance and peer review Not commissioned; externally peer reviewed.
Read the full text or download the PDF:
Other content recommended for you
- Why using Avastin for eye disease is so difficult
- Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD
- Patient-reported reasons for delay in diagnosis of age-related macular degeneration: a national survey
- Off-label use of bevacizumab in the treatment of retinal disease: ethical implications
- Implications of “not me” drugs for health systems: lessons from age related macular degeneration
- Why have UK doctors been deterred from prescribing Avastin?
- What is stopping the NHS from using bevacizumab for macular degeneration and other retinal disorders?
- Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)
- Are the odds shifting against pharma in the fight for cheaper treatment for macular degeneration?
- Different antivascular endothelial growth factor treatments and regimens and their outcomes in neovascular age-related macular degeneration: a literature review